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BACKGROUND
Over 30,000 new cases of non-Hodgkin’s lymphoma are
diagnosed each year in the United States [1]. While current
therapies have produced signiﬁcant complete response rates,
a large percentage of patients remain at signiﬁcant risk for
disease relapse [2]. Immune-based strategies for targeting
minimal residual disease are under development and may
provide additional modalities for consolidating standard
chemotherapy, radiotherapy, and transplant regimens. The
approach of treating lymphoma with adoptive T-cell therapy
is predicated on the assumptions that tumor-reactive T cells
can be isolated from individuals with lymphoma and expand-
ed in vitro and that infusion of the expanded effector popula-
tion into the patient will mediate an antitumor effect without
significant toxicity. Adoptively transferred donor-derived
Epstein-Barr virus (EBV)-specific T cells can eliminate
transformed B cells as demonstrated in the setting of post-
transplant EBV-associated lymphoproliferative disease [3].
The clinical application of cellular immunotherapy for lym-
phoma using autologous T cells is currently limited by the
paucity of molecularly deﬁned lymphoma target antigens for
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ABSTRACT
The CD20 molecule was evaluated as a B-cell lymphoma target epitope for T cells expressing a CD20-specific sin-
gle-chain FvFc-zeta (scFvFc:) chimeric receptor. A cDNA construct consisting of a murine kappa leader sequence,
CD20-specific scFv, human immunoglobulin (Ig) G1 hinge-CH2-CH3, the human CD4 transmembrane, and the
intracellular signaling domain of the human CD3 complex’s  chain was synthesized by polymerase chain reaction
splice-overlap extension. The human CD4 Jurkat cell line was electroporated with the CD20-specific scFvFc:
construct cloned into the mammalian expression vector pcDNAneo. Western blot analysis of transfectant whole cell
lysate with an anti- antibody demonstrated the expression of both endogenous  and the chimeric receptor protein,
with a mobility consistent with the expected molecular weight of 66 kD under reducing conditions; nonreduced
lysate revealed a chimeric receptor complex of 132 kD. The scFvFc: receptor was present on the cell surface as
detected by flow cytometry of T-cell transfectants stained with an anti-mouse Fab-specific antibody and anti-human
Fc-specific monoclonal antibody. Coculture of Jurkat transfectants with CD20 lymphoma cells resulted in the
accumulation of interleukin (IL)-2 in culture supernatants as detected by ELISA. IL-2 production was triggered by
the specific interaction between the CD20 molecule and the scFvFc: as IL-2 was not detected in cultures with
mock transfected Jurkat cells or CD20 stimulator cells. Furthermore, IL-2 production was inhibited by the addi-
tion of a soluble anti-CD20 monoclonal antibody to cocultured Jurkat transfectants and CD20 stimulator cells.
The capacity of CD20 to trigger the lytic machinery of scFvFc:-expressing cytotoxic T lymphocytes (CTLs) was
assessed using the murine allo-specific CD8 CTL clone 2c. CD20-specific redirected cytolytic activity against
human lymphoma targets was observed with 2c transfectants in a 4-hour chromium release assay. These results
demonstrate that CD20 can serve as a target epitope for scFvFc: receptor-expressing T cells.
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T-cell recognition and the challenges of reliably isolating and
expanding tumor antigen-specific T-cell responses from
cancer patients.
To overcome these obstacles, we and others are evaluat-
ing chimeric antigen receptor constructs that consist of a
monoclonal antibody single-chain Fv (scFv) linked to the
intracellular signaling domain of CD3 or FcRIII to redi-
rect T-cell speciﬁcity. This strategy allows targeting of tumor
cells based on the binding of the scFv portion of the receptor
to monoclonal antibody-deﬁned cell-surface epitopes. The
capacity of these receptors, when expressed in T cells, to trig-
ger cytokine production and cytolysis in vitro is now well
established in both murine and human T cells [4–9]. Animal
model systems demonstrate the capacity of murine T-cell
transfectants to eradicate tumors in vivo, suggesting that
these gene-modified cells retain appropriate homing and
recycling mechanisms [10]. This system is not dependent on
pre-existing antitumor immunity; the generation of tumor-
reactive T cells for therapy can be accomplished by the
genetic modiﬁcation of polyclonal T cells present in periph-
eral blood. Moreover, target epitope recognition via an scFv
is not human leukocyte antigen (HLA)-restricted, thus per-
mitting the use of receptor constructs in populations of lym-
phoma patients irrespective of HLA differences.
A critical aspect of this chimeric receptor strategy is the
selection of target epitopes that are speciﬁcally or selectively
expressed on tumor cells, that are present on all tumor cells,
and that are membrane epitopes not prone to shed or modu-
late from the cell surface. Nearly 80% of non-Hodgkin’s
lymphoma are B cell in origin and deﬁned in part by the cell
surface expression of the CD20 molecule. This 33–37 kD
protein is uniformly expressed on normal pre-B cells and
malignant B cells at a density greater than 12,000 molecules
per cell [11]. CD20 does not modulate or shed from the cell
surface and has structural features consistent with that of an
ion channel [12,13]. The FDA has approved a chimeric
CD20-speciﬁc monoclonal antibody for lymphoma therapy.
Initial clinical experience with CD20-targeted immunothera-
py suggests that malignant B cells may have a limited capacity
to downregulate CD20 expression [unpublished observations,
A.R.]. These attributes make CD20 an attractive target for
scFvFc:-redirected T cells. A CD20-specific scFvFc was
assembled from hybridoma cDNA; a soluble scFvFc mole-
cule was expressed and shown to mimic the speciﬁcity of the
parental monoclonal antibody. We here report our ﬁndings
of the structural and functional properties of a CD20-speciﬁc
scFvFc: receptor construct expressed in T cells.
MATERIALS AND METHODS
Assembly of a CD20-specific scFvFc: construct
The chimeric CD20-speciﬁc T cell receptor (TCR) gene
was assembled by splice-overlap polymerase chain reaction
(PCR) based on the design of Roberts et al. [14]. Sources of
template DNA were as follows: anti-CD20 variable region
genes were cloned by reverse transcriptase (RT)-PCR from
the murine hybridoma Leu-16 (Becton Dickinson Immuno-
cytometry Systems, San Jose, CA); the human immuno-
globulin (Ig) G1 heavy chain gene was the generous gift of
Jeffrey Schlom, PhD (National Cancer Institute); the human
CD4 clone was obtained from the AIDS Research and Ref-
erence Reagent Program (Rockville, MD). The human CD3
complex -chain was cloned by RT-PCR from Jurkat cells,
using primers based on the sequence of Weissman et al. [15].
The ﬁnal chimeric construct consisted of a Kozak consensus
ribosome-binding sequence, murine kappa chain signal pep-
tide; VL; 18-residue linker peptide; VH; hinge-CH2-CH3;
CD4 transmembrane region (residues 372–393 of the mature
protein); and the cytoplasmic domain of the  chain (residues
31–142 of the mature protein). Flanking XbaI and NotI
restriction sites were included to facilitate cloning of the
DNA sequence into the mammalian expression vector
pcDNAneo under the control of the cytomegalovirus (CMV)
immediate-early promoter (Invitrogen, San Diego, CA).
Correct assembly was conﬁrmed by DNA sequence analysis
of the final product. The expressed receptor construct is
schematically represented in Figure 1.
In vitro propagation of cell lines
The Jurkat, Daudi, P815, and K562 cell lines were
obtained from ATCC (Rockville, MD), the murine allo-spe-
ciﬁc cytotoxic T lymphocyte (CTL) clone 2c was originated
by David Kranz, PhD, of the University of Chicago, and the
human lymphoma cell line DHL-6 was the kind gift of
Michael Cleary, MD, of Stanford University Medical Cen-
ter. EBV-transformed lymphoblastoid cell lines (LCL) were
generated from human EBV-infected peripheral blood lym-
phocytes in the presence of cyclosporin [16]. Cells were
grown in RPMI 1640 (GIBCO, Grand Island, NY) supple-
mented with 2 mmol of L-glutamine (Irvine Scientiﬁc, Santa
Ana, CA), 25 mmol of HEPES (Irvine Scientific), 100
U/mL of penicillin, 0.1 mg/mL of streptomycin (Irvine Sci-
entiﬁc), and 10% heat-inactivated fetal calf serum (Hyclone,
Logan, UT). 2c clones were maintained in culture by res-
timulating cells every 14 days with irradiated P815 cells.
Supplemental human interleukin (IL)-2 (50 U/mL; Cetus,
Emeryville, CA) was added to 2c cells every 48 hours.
Figure 1. Schematic representation of the CD20-specific scFvFc:
chimeric receptor
Hinge-C H 2-C H 3
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Electroporation and selection procedure
pcDNAneo containing the anti-CD20 scFvFc: construct
was linearized at a unique PvuI site in the plasmid’s ampicillin
resistance gene. Linearized plasmid was introduced into
Jurkat and 2c clones by electroporation using the BTX Elec-
tro Cell Manipulator 600 (Genetronics, San Diego, CA) set at
250 V, 975 F, 186 ohms. Jurkat (2107 log phase) or 2c cells
harvested 4 days after antigen stimulation were aliquoted into
0.4-cm electroporation cuvettes in 0.8 mL of phosphate-
buffered saline (PBS) with 10 mmol of MgCl2. Plasmid (50
g) in sterile water was added and incubated for 10 minutes
on ice. After electroporation, cells were again incubated on
ice for 10 minutes before being resuspended in culture media.
Forty-eight hours after electroporation, cells were plated in
media containing 1 mg/mL of G418 (Mediatech, Herndon,
VA). Drug-resistant transfected Jurkat cells were cloned in
limiting dilution and then expanded for further analysis.
Western blot procedure
Whole cell lysates of parental Jurkat and 2c cells or their
scFvFc: transfectants were generated by lysis of 2107
washed cells in 1 mL of RIPA buffer (PBS, 1% NP40, 0.5%
sodium deoxycholate, 0.1% sodium dodecyl sulfate [SDS])
containing 1 tablet/10 mL of Complete Protease Inhibitor
Cocktail (Boehringer Mannheim, Indianapolis, IN) and
incubated on ice for 80 minutes. Samples of centrifuged
lysate supernatant were harvested and boiled in an equal vol-
ume of loading buffer under reducing and nonreducing con-
ditions, then subjected to SDS-PAGE electrophoresis on a
precast 12% acrylamide gel (BioRad, Richmond, CA). After
transfer to nitrocellulose, membranes were blocked in blotto
solution containing 0.07 g/mL of nonfat dried milk for 2
hours. Membranes were then incubated with primary mouse
anti-human CD3 monoclonal antibody 8D3 (Pharmingen,
San Diego, CA) at a concentration of 1 g/mL for 2 hours,
and washed and incubated again with a 1:500 dilution of goat
anti-mouse IgG alkaline phosphatase-conjugated secondary
antibody for 1 hour. Before developing, membranes were
washed 4 additional times in Tris-buffered saline with Tween
(0.05% Tween 20 in Tris-buffered saline with pH 8.0). Mem-
branes were then developed with 30 mL of the manufactur-
er’s AKP solution (Promega, Madison, WI).
FACS analysis
Jurkat cells and 2c cells were stained with a ﬂuorescein
isothiocyanate (FITC)-conjugated goat anti-mouse Fab-spe-
cific polyclonal antibody (Sigma, St. Louis, MO) and an
FITC-conjugated monoclonal mouse anti-human IgG, Fc
fragment-specific F(ab')2 (Jackson ImmunoResearch, West
Grove, PA) for analysis of cell surface chimeric receptor
expression. Cells (106) were washed and resuspended in 100
L of PBS containing 2% fetal calf serum, 0.2 mg/mL
NaN3, and 2 L of antibody. After a 60 minute incubation
on ice, cells were washed 3 times and resuspended in PBS
containing 1% paraformaldehyde and analyzed on a MoFlo
cytometer (Cytomations, Fort Collins, CO).
In vitro stimulation of cytokine production
Jurkat cells expressing the chimeric CD20-specific
scFvFc: receptor were evaluated for receptor-mediated
triggering of IL-2 production in vitro. Jurkat responder cells
(5105) were cocultured in 48-well tissue culture plates
(Costar, Cambridge, MA) with an equal number of irradiat-
ed stimulator cells in a 1 mL volume. Blocking anti-CD20
Leu-16 monoclonal antibody was added to indicated wells
containing stimulator cells at a concentration of 20 g/mL
30 minutes before the addition of responder cells. Plates
were incubated for 48 hours when culture supernatants were
harvested and evaluated for IL-2 protein concentration. An
ELISA assay for IL-2 was carried out using the R&D Sys-
tems kit (Minneapolis, MN) per manufacturer instructions.
Each sample, undiluted and diluted 1:5, was tested in dupli-
cate wells. The developed ELISA plate was evaluated on a
microplate reader and IL-2 concentrations determined by
extrapolation from a standard curve. Results are reported as
picograms/mL.
Chromium release assay
The cytolytic activity of 2c and 2c transfectants was
assayed by using 51Cr-labeled P815, K562, Daudi, DHL-6,
and LCL. Brieﬂy, 2c effectors were assayed 8–12 days after
stimulation with irradiated P815 cells. Effectors were harvest-
ed, washed, and resuspended in assay media; 2.5105, 1105,
0.5105, and 0.1105 effectors were cultured in triplicate at
37C for 4 hours with 104 target cells in V-bottom microtiter
plates (Costar, Cambridge, MA). After centrifugation and
incubation, 100 aliquots of cell-free supernatant were har-
vested and counted. Percent speciﬁc cytolysis was calculated
as follows:
(experimental 51Cr release) – (control 51Cr release)
 100
(maximum 51Cr release) – (control 51Cr release)
Control wells contained target cells incubated in the pres-
ence of media alone. Maximum 51Cr released was deter-
mined by directly measuring the 51Cr content of labeled
cells in the presence of 2% SDS.
RESULTS
CD20-specific scFvFc: receptor protein expressed in Jurkat
and 2c cells
To determine whether the CD20-speciﬁc scFvFc: con-
struct could be expressed as an intact chimeric protein, Jurkat
and 2c cells were transfected with the receptor cDNA cloned
into pcDNAneo under the transcriptional control of the
CMV immediate-early promoter. Jurkat clones were isolated
by limiting dilution and 2c transfectants were maintained as a
bulk line. A Western blot of reduced and nonreduced trans-
fectant whole cell lysates separated on a 12% SDS-PAGE gel
demonstrated the presence of endogenous  with a molecular
weight of 16 kD and a band corresponding to the expected
molecular weight of the CD20-speciﬁc scFvFc: receptor (66
kD; Fig. 2). When lysates were generated under nonreducing
conditions, the endogenous  band migrated at 32 kD as
expected for a homodimer and the chimeric receptor band
migrated at a molecular weight of 132 kD.
CD20-specific scFvFc: receptor protein on the cell surface
of Jurkat and 2c cells
Export of the CD20-specific receptor to the plasma
membrane of Jurkat and 2c cells was assessed by ﬂow cyto-
M Jensen et al.
78
metric analysis of transfectants with an FITC-conjugated
goat anti-mouse Fab-speciﬁc antibody and a goat anti-human
Fc antibody. The murine Fab epitope is expected to be
reconstituted in the scFv portion of the chimeric receptor and
the human Fc epitope is the membrane proximal portion of
the receptor’s extracellular domain. As detected with FITC-
conjugated anti-Fab antibody, analysis of the surface expres-
sion of the chimeric receptor on a representative Jurkat clone
transfectant 3 weeks after electroporation showed a log shift
in ﬂuorescence compared with that on parental Jurkat cells
(Fig. 3A). Similar analysis of a bulk population of 2c transfec-
tants stained with anti-human Fc revealed a similar pattern
of binding of the FITC-conjugated antibody (Fig. 3B). The
Fc epitope was also detected on Jurkat transfectants, and the
murine Fab epitope on 2c transfectants (data not shown).
Receptor expression remained stable over a 3-month period
of continuous culture of cells in G418 (data not shown).
CD20 expressed on lymphoma cells triggers IL-2 production
by Jurkat cells expressing the CD20-specific scFvFc: receptor 
The capacity of the CD20-speciﬁc scFvFc: receptor to
transduce an activation signal in Jurkat cells sufficient for
triggering IL-2 production was determined by culturing
Jurkat transfectant clones with CD20-expressing lymphoma
cells in vitro and quantitating IL-2 concentration in super-
natants by ELISA. Figure 4 is a representative experiment
(reproduced 3 times) in which parental Jurkat cells produced
IL-2 in response to mitogenic doses of OKT3 in combina-
tion with phorbol myristate acetate (PMA), but did not pro-
duce IL-2 when cocultured with CD20 K562 cells or
CD20	 DHL-6 or LCL. In contrast, Jurkat transfectants
expressing the CD20-specific scFvFc: receptor produced
IL-2 when cocultured with CD20	 lymphoma cells. The
addition of the CD20-speciﬁc monoclonal antibody Leu-16
to cocultured Jurkat transfectants and LCL decreased IL-2
concentrations measured in supernatants by 60%.
CD20 expressed on lymphoma cells triggers cytolytic activi-
ty of 2c cells expressing the CD20-specific scFvFc: receptor 
2c is an extensively characterized murine cytolytic T cell
clone speciﬁc for H-2d [17]. This clone requires both anti-
gen stimulation and IL-2 for in vitro propagation. Electro-
porated 2c cells were selected in bulk with G418. After con-
ﬁrmation of scFvFc: expression by Western blot and FACS,
this cell line was evaluated for redirected CD20-specific
cytolytic activity in a 4-hour chromium release assay. Lysis
Figure 2. Western blot analysis of CD20-specific scFvFc: expression by Jurkat and 2c transfectants
Whole cell lysates of parental Jurkat, stably transfected Jurkat clones, parental 2c cells, and 2c bulk transfectants were evaluated in reduced and nonreduced states.
These photographs of a 12% SDS-PAGE of lysates probed with the mouse anti-human  IgG clone 8D3 were developed with an alkaline phosphatase-conjugated
secondary antibody. Molecular weight markers are indicated to the left of each blot.
Nonreduced Gel 12%Reduced Gel 12%
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of CD20	 human lymphoma targets Daudi, DHL-6, and
LCL was observed by 2c transfectants, and the parental and
transfected lines displayed equivalent lysis of P815, a murine
H-2d mastocytoma line recognized by 2c via its endogenous
TCR (Fig. 5). Neither parental nor scFvFc: 2c transfec-
tants lysed the CD20 target K562. The transfected cell line
was retested for CD20-specific cytolytic activity over a 3-
month period and was found to have stable lytic activity
(data not shown).
DISCUSSION
The strategy of isolating and expanding antigen-speciﬁc
T cells as a therapeutic intervention for human disease has
been validated in clinical trials [18–20]. Initial studies have
evaluated the utility of adoptive T-cell therapy with
CD8	CTL clones speciﬁc for CMV-encoded antigens as a
means of reconstituting deﬁcient viral immunity in the set-
ting of allogeneic bone marrow transplantation (BMT), and
have defined the principles and methodologies for T-cell
isolation, cloning, expansion, and reinfusion [18]. A similar
approach has been used to control posttransplant EBV-asso-
ciated lymphoproliferative disease. EBV-specific donor-
derived T cells have the capacity to protect patients at high
risk for this complication and to eradicate clinically evident
disease that mimics immunoblastic B-cell lymphoma [20].
These studies clearly demonstrate that adoptively trans-
ferred ex vivo–expanded T cells can mediate antigen-speciﬁc
effector functions with minimal toxicities, and have been
facilitated by targeting deﬁned virally encoded antigens to
which T-cell donors have established immunity.
Applying adoptive T-cell therapy as a treatment modality
for human malignancy has been limited by the paucity of
molecularly deﬁned tumor antigens capable of eliciting a T-
cell response and by the difﬁculty of isolating these T cells
from the tumor-bearing host. Consequently, initial cellular
immunotherapy trials, using autologous antitumor effector
cells, relied on antigen-nonspeciﬁc effector cells such as lym-
phokine-activated killer cells, which had limited efﬁcacy and
pronounced toxicities [21]. To enhance the tumor speciﬁcity
of infused effector cells, IL-2–expanded tumor-infiltrating
lymphocytes (TIL) were evaluated [22]. Responses to TIL
infusions were sporadic in part due to the heterogeneous
population of cells expanded with unpredictable antitumor
speciﬁcities. Patients with melanoma and renal cell carcino-
ma, however, occasionally manifested striking tumor regres-
sions after TIL infusions, and tumor-specific major histo-
compatibility (MHC)-restricted T-cell clones have been iso-
lated from these patients. Recently, expression cloning tech-
nologies have been developed to identify the genes encoding
tumor antigens, thereby facilitating the development of both
recombinant DNA-based vaccine strategies to initiate or aug-
ment host antitumor immunity and in vitro culture systems to
generate tumor-specific T cells from cancer patients [23].
Clinical trials using autologous tyrosinase-speciﬁc CTL for
the treatment of melanoma are currently under way and will
likely provide major insights into the efficacy of targeting
tumors with antigen-speciﬁc MHC-restricted T-cell clones
[S. Riddell, personal communication].
The inclusion of hematologic malignancies as targets for
T-cell therapy is warranted based on the graft-vs.-leukemia
(GVL) effect observed in the setting of allogeneic BMT and
the anti-leukemic activity of donor buffy coat infusions [24].
Currently, it is clear that T cells present in the marrow graft
mount a response to host minor histocompatibility antigens
that contribute to graft-vs.-host disease (GHVD). There is
increasing evidence that there may be T-cell speciﬁcities for
GVL that are distinct from those of GVHD on the basis of
restricted tissue expression of a subset of minor histocompati-
bility antigens [25]. Nevertheless, the susceptibility of malig-
nant B cells to CTL recognition and lysis is well documented
[26,27]. Efforts to target B-cell lymphoma with MHC-
restricted CTL have focused on the lymphoma clone’s idio-
type as a tumor-speciﬁc antigen. Murine models have demon-
strated that CTL responses can be generated to Ig variable
regions and that lymphoma cells process and present these
determinants for T-cell recognition [28,29]. Although these
Figure 3. Flow cytometric detection of cell-surface scFvFc: on
Jurkat and 2c transfectants
(A) Parental Jurkat cells and Jurkat scFvFc:-expressing clone C2P3D3
were stained with FITC-conjugated goat anti-mouse Fab-specific absorbed
polyclonal antibody and relative fluorescence determined by flow cytometry. 
(B) Parental and 2c bulk transfectants were stained with an FITC-conjugat-
ed mouse anti-human Fc-speciﬁc F(ab')2 antibody.
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strategies are potentially tumor-speciﬁc, they are also patient-
speciﬁc, thus making large-scale application difﬁcult.
Endowing T cells with a desired antigen specificity
based on genetic modification with engineered receptor
constructs is an attractive strategy because it bypasses the
requirement for retrieving antigen-specific T cells from
cancer patients and, depending on the type of antigen
recognition moiety, allows for targeting tumor cell-surface
epitopes unavailable to endogenous T-cell receptors. Studies
to deﬁne the signaling function of individual components of
the TCR-CD3 complex revealed that chimeric molecules
with intracellular domains of the CD3 complex’s  chain
coupled to extracellular domains, which could be crosslinked
by antibodies, were capable of triggering biochemical as well
as functional activation events in T-cell hybridomas [30].
Recent advances in protein engineering have provided
methodologies to assemble single-chain molecules consist-
ing of antibody variable regions connected by a ﬂexible pep-
tide linker that recapitulates the speciﬁcity of the parental
antibody [31]. Several groups have now reported on the
capacity of chimeric single-chain receptors consisting of an
extracellular scFv and intracellular  domain to redirect T-
cell speciﬁcity to tumor cells expressing the antibody’s target
epitope; receptor speciﬁcities have included Her2/neu, and
less well-characterized epitopes on renal cell and ovarian
carcinoma [4–9]. An idiotype-speciﬁc scFv chimeric TCR,
which recognizes the idiotype-expressing lymphoma cell’s
surface Ig as its ligand, has been described [32]. Although
this approach replaces a low-afﬁnity MHC-restricted TCR
complex for a high-affinity MHC-unrestricted molecule
linked to an isolated member of the CD3 complex, these
receptors do activate T cell effector functions in primary
human T cells without apparent induction of subsequent
anergy or apoptosis [9]. Murine model systems using scFv:-
transfected CTL demonstrate that tumor elimination only
occurs in vivo if both cells and IL-2 are administered, thus
suggesting that, in addition to activation of effector func-
tion, signaling through the chimeric receptor is sufficient
for T-cell recycling [10].
Our studies represent the ﬁrst attempt to target a univer-
sal B-cell lymphoma cell-surface epitope with scFvFc: redi-
rected T cells. Malignant B cells appear to be an excellent
target for redirected T cells because they can serve as
immunostimulatory antigen-presenting cells for T cells [33].
IL-2 production by the CD20-speciﬁc scFvFc:-expressing
Jurkat clones when cocultured with CD20	 lymphoma did
not require the addition of professional antigen-presenting
cells to culture or pharmacologic delivery of an additional
signal by the phorbol ester PMA. The capacity of B-cell lym-
phoma cells to deliver costimulatory signals in our model
Figure 4. CD20 lymphoma cells trigger IL-2 production by Jurkat cells expressing the CD20-specific scFvFc: receptor
Parental Jurkat cells and stably transfected Jurkat clone C2P3D3 were plated at 5105 cells/well in 48-well tissue culture plates containing the indicated reagents
or 5105 stimulator cells. After 48 hours, supernatants were harvested and evaluated by ELISA for IL-2 concentration per manufacturer instructions. IL-2 was
measured in duplicate ELISA wells. Anti-CD20 Leu-16 was added to LCL stimulator cells at room temperature 30 minutes before transfer to wells containing
Jurkat responder cells. 
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system is supported by our observation that Jurkat cells
express the CD28 receptor, and B-cell lymphoma lines used
in this study are CD80	 by flow cytometry (unpublished
data). Immunohistochemical evaluation of lymphoma-con-
taining lymph node specimens have detected CD80 expres-
sion by malignant B cells [34]. These observations support
the rationale for evaluating the adoptive transfer of scFvFc:-
expressing CD4	 TH1 cells in combination with CD8
	CTL,
based on their ability to produce IL-2 at tumor sites where
they can support the expansion of transferred CTL. CD28
signalling has recently been reported to inhibit activation-
induced cell death of CTL when delivering a lytic event to
tumor target cells, and may contribute to the ease by which
CTL are expanded in vitro and potentially in vivo when stim-
ulated with transformed B cells such as LCL [35].
Lymphoma, by virtue of its lymph node tropism, is ideally
situated anatomically for T-cell–mediated recognition and
elimination. The localization of infused T cells to lymph
nodes in large numbers has been documented in HIV patients
receiving infusions of HIV-specific CD8	CTL clones. In
these patients, evaluation of lymph node biopsy material
revealed that infused clones constituted approximately 2–8%
of CD8	 lymph node T cells [S. Riddell, personal communi-
cation]. Lymph node homing might be further improved by
cotransfecting T cells with a cDNA construct encoding the L-
selectin molecule under a constitutive promoter because this
adhesion molecule directs circulating T cells back to lymph
nodes and is down-regulated by in vitro expansion [36].
The CD20 molecule appears to be an ideal target epitope
for recognition by scFvFc:-expressing T cells because of the
prevalence of CD20	 disease, the uniformity of expression by
tumor cells, and the stability of the CD20 molecule on the
cell surface. In addition to antitumor effector mechanisms
intrinsic to T cells, it has been recently reported that CD20
crosslinking by soluble antibody can trigger apoptosis in
selected B-cell lymphoma lines; such a killing mechanism
may contribute to the biologic activity of CD20-specific
scFvFc:-expressing T cells in vivo [37]. CD20, however, is
not tumor-speciﬁc and the adoptive transfer of cells with this
speciﬁcity is expected to kill the subset of nontransformed
pre-B cells, which express CD20. Although CD20 is not
expressed by hematopoietic stem cells or mature plasma cells,
this cross-reactivity may exacerbate the humoral immuno-
deﬁciency of patients receiving chemotherapy or radiothera-
py. Equipping T cells with a suicide gene such as the herpes
virus thymidine kinase gene allows for in vivo ablation of
transferred cells after adoptive transfer with pharmacologic
doses of gancyclovir and is a strategy for limiting the duration
of in vivo persistence of transferred cells [38]. 
Evaluation of the efficacy of CD20-specific scFvFc:-
expressing T cells is indicated for patients with CD20	
non-Hodgkin’s lymphoma and CD20	 acute and chronic
leukemias. High relapse rates observed after autologous
transplantation for leukemia may be reduced with post-
transplant in vivo purging with adoptively transferred
CD20-specific T cells. Further preclinical evaluation of
CD20	 leukemic samples will be needed to establish the
presence of the CD20 epitope on leukemic stem cells to jus-
tify the evaluation of CD20-directed cellular immunotherapy
in conjunction with autologous transplantation. Pilot phase I
trials will evaluate the toxicity of adoptive transfer in lym-
phoma patients with refractory or recurrent disease. Howev-
er, the most logical time for using these gene-modified T
cells is shortly after myeloablative chemotherapy and stem
cell rescue because tumor burden and normal CD20	 cell
burden would be at a nadir. Additionally, the potential of an
immunologic response directed against the scFvFc: protein,
which may limit the persistence or interfere with the func-
tion of infused gene-modiﬁed T cells, is minimized in the
early phases of recovery from high-dose chemotherapy. 
Figure 5. CD20 lymphoma cells are lysed by CD8 2c CTL expressing the CD20-specific scFvFc: receptor
Parental and 2c bulk transfectants were harvested 10 days following stimulation with irradiated P815 cells and IL-2, washed, and plated at the indicated effector
to target ratios with 104 target cells labeled with 51Cr. After a 4-hour incubation assay, plates were harvested and radioactivity in supernatants measured on a
gamma counter. Percent speciﬁc lysis was calculated by the formula detailed in Materials and Methods. Spontaneous release for each target was less than 10%. The
data presented are from a representative assay that has been repeated 5 times.
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Our efforts are currently focused on the preclinical
development of efﬁcient nonretroviral gene transfer systems
using naked DNA and optimized electroporation parame-
ters for primary human T cells. Preliminary data generated
in our laboratory demonstrate that this is feasible and per-
mits the rapid evaluation of construct modifications for
functional optimization. Plasmid-based strategies also allow
for increased ﬂexibility with respect to the size and sequence
of cDNA inserts over retroviral vectors. Improved dicistron-
ic expression vectors, which co-select for chimeric receptor
expression and drug resistance, are expected to make
chimeric receptor expression obligatory in drug-resistant
cells. Furthermore, because the scFvFc: moiety is a unique
cell surface epitope for identifying transfected cells, FACS-
based sorting technologies may allow for the rapid retrieval
of scFvFc:-expressing T cells for expansion after transfec-
tion. Finally, under development are T cell expansion proto-
cols based on stimulating transfectants with CD20	 stimula-
tor cells, recombinant CD20, or scFvFc:-speciﬁc crosslink-
ing with an antibody to expand clones with receptor expres-
sion levels optimized for functional activity. The anti-lym-
phoma activity of T cells expressing this CD20-specific
scFvFc: receptor derived from patients with lymphoma is
currently being evaluated.
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